Articles Vol. 65 No. CĐ 3 - Bệnh viện Phổi Trung ương 15/05/2024

2. EVALUATION OF ACCURACY OF XPERT MTB/XDR TESTING REGARDING DETECTION FOR DRUG RESISTANCE OF ISONIAZID, FLUOROQUINOLONES, INJECTABLE DRUGS AT NATIONAL LUNG HOSPITAL

Dinh Thi Huong1,2, Doan Thu Ha1,2, Le Thi Nam1,2, Dinh Thi Phuong Thanh3,4
1 National Lung Hospital
2 Bệnh viện Phổi Trung ương
3 University of Medicine and Pharmacy - Hanoi National University
4 Đại học Y Dược - Đại học Quốc gia Hà Nội
Corresponding author: dinhhuongtb90@gmail.com
DOI: 10.52163/yhc.v65iCD3.1097
25 Views
17 Downloads
Keywords
Xpert MTB/XDR, drug resistance.
Abstract

Objective: To evaluate the accuracy of Xpert MTB/XDR regarding detection for drug resistance of INH, FLQ and injectable drugs.

Methods: 100 RR-TB patients were tested for drug resistance detection by Xpert MTB/XDR test, MTB firstline, secondline LPA test and phenotypic drug susceptibility testing, a cross-sectional study.

Results: The sensitivity of Xpert MTB/XDR testing regarding drug resistance detection was 98.85% for INH, 80% for FLQ, 83.33% for AMK, 100% for KAN and CAP. The specificity for all drugs resistance detection achieved 95%-100%. Positive Prediction Value (PPV) ranged among 94-100%, except KAN’s with 85.71% and CAP’s with 33.33%. Negative Prediction Value (NPV) for all drugs obtained 92%-100%. Concordance based on Cohen's kappa value between Xpert MTB/XDR and MTB firstline, secondline LPA ranged 0.9-1.0 regarding INH/ FLQ resistance detection, 0.6-0.7 for AMK, KAN and CAP resistance detection.

Conclusion: Xpert MTB/XDR testing had high sensitivity and specificity in INH, FLQ, and injectable drugs resistance detection as well as obtained high concordance when compared with MTB firstline, secondline LPA. Xpert MTB/XDR testing is considered as a rapid, simple molecular drug resistance test which would be an effective diagnosis tool for Vietnam National TB Control Program to improve the coverage of diagnostic tests for detection of drug resistance in the upcoming time.

References
[1]
Global tuberculosis report 2023. Geneva: World Google Scholar
[2]
Health Organization; 2023. Licence: CC BYNC-SA 3.0 IGO. Google Scholar
[3]
Vietnam TB Profile Report, 2022, WHO. Google Scholar
[4]
Technical manual for drug susceptibility testing Google Scholar
[5]
of medicines used in the treatment of tuberculosis. Google Scholar
[6]
Licence: CC BY-NC-SA 3.0 IGO. Google Scholar
[7]
GLI Practical Guide to TB Laboratory Strengthening, Google Scholar
[8]
Geneva, World Health Organization, 2017. Google Scholar
[9]
Cepheid. Xpert MTB/XDR [website]. 2021 Google Scholar
[10]
(https://www.cepheid.com/en/tests/ Critical- Google Scholar
[11]
Infectious-Diseases/Xpert-MTB-XDR). Google Scholar
[12]
WHO consolidated guidelines on tuberculosis. Google Scholar
[13]
Module 3: Diagnosis – rapid diagnostics for Google Scholar
[14]
tuberculosis detection, third edition. Geneva: Google Scholar
[15]
World Health Organization; 2024. Licence: CC Google Scholar
[16]
BY-NC-SA 3.0 IGO. Google Scholar
[17]
Update on the use of nucleic acid amplification Google Scholar
[18]
tests to detect TB and drug-resistant TB: Rapid Google Scholar
[19]
communication. Geneva: World Health Organization; Google Scholar
[20]
(https://www.who.int/publications/i/item/update- Google Scholar
[21]
on-the-use-of-nucleic-acid-amplification-tests-to- Google Scholar
[22]
detect-tb-and-drug-resistant-tbrapid-communication. Google Scholar
[23]
Penn-Nicholson A, Georghiou SB, Ciobanu N Google Scholar
[24]
et al., Detection of isoniazid, fluoroquinolone, Google Scholar
[25]
ethionamide, amikacin, kanamycin, and capreomycin Google Scholar
[26]
resistance by the Xpert MTB/XDR assay: A cross- Google Scholar
[27]
sectional multicentre diagnostic accuracy study. Google Scholar
[28]
The Lancet Infectious Diseases. 2022;22(2):242-9. Google Scholar
[29]
Cao Y, Parmar H, Gaur RL et al., Xpert MTB/ Google Scholar
[30]
XDR: A 10-Color Reflex Assay Suitable for Google Scholar
[31]
Point-of-Care Settings To Detect Isoniazid, Google Scholar
[32]
Fluoroquinolone, and Second-Line-Injectable-Drug Google Scholar
[33]
Resistance Directly from Mycobacterium tuberculosis- Google Scholar
[34]
Positive Sputum. Journal of clinical microbiology. 2021;59(3). Google Scholar
[35]
Syed RR, Catanzaro DG, Colman RE et al., Google Scholar
[36]
Clinical Evaluation of the XDR-LFC Assay for Google Scholar
[37]
the Molecular Detection of Isoniazid, Rifampin, Google Scholar
[38]
Fluoroquinolone, Kanamycin, Capreomycin, Google Scholar
[39]
and Amikacin Drug Resistance in a Prospective Cohort. Google Scholar
[40]
Journal of clinical microbiology. 2023;61(3):e0147822. Google Scholar
[41]
Katamba A, Ssengooba W, Sserubiri J et al., Google Scholar
[42]
Evaluation of Xpert MTB/XDR test for susceptibility Google Scholar
[43]
testing of Mycobacterium tuberculosis Google Scholar
[44]
to first and second-line drugs in Uganda. PLOS Google Scholar
[45]
ONE. 2023;18(8):e0284545. Google Scholar
[46]
Bộ Y tế, Hướng dẫn Chẩn đoán, điều trị và dự Google Scholar
[47]
phòng bệnh Lao, Quyết định 162/QĐ-BYT 2024, Bộ Y tế. Google Scholar
[48]
Nguyen HB, Nguyen NV, Tran HT et al., Prevalence Google Scholar
[49]
of resistance to second-line tuberculosis drug among Google Scholar
[50]
multidrug-resistant tuberculosis patients in Viet Nam, Google Scholar
[51]
Western Pacific surveillance and response journal : Google Scholar
[52]
WPSAR. 2016;7(2):35-40. Google Scholar